8980 Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Biomaterials, Delivery Systems, and 

Nanotechnology. 

Date: March 15–16, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Alexander Gubin, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6046B, 

MSC 7892, Bethesda, MD 20892. 301–408– 

9655. gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: HIV Behavior Chartered. 

Date: March 25, 2010. 

Time: 8 a.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Hilary D. Sigmon, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892. (301) 594– 

6377. sigmonh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Review of 

Member Conflict Applications. 

Date: March 29, 2010. 

Time: 11 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jose H. Guerrier, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892. 301–435– 

1137. guerriej@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 19, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–3908 Filed 2–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3223–N] 

Medicare Program; Meeting of the 

Medicare Evidence Development and 

Coverage Advisory Committee—April 

21, 2010 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces that a 

public meeting of the Medicare 

Evidence Development & Coverage 

Advisory Committee (MEDCAC) 

(‘‘Committee’’) will be held on 

Wednesday, April 21, 2010. The 

Committee generally provides advice 

and recommendations concerning the 

adequacy of scientific evidence needed 

to determine whether certain medical 

items and services should be covered 

under the Medicare statute. This 

meeting will focus on the currently 

available evidence regarding the risks, 

benefits, and outcomes of radiation 

therapy, inclusive of external beam 

radiotherapy (EBRT) and brachytherapy, 

for the treatment of localized prostate 

cancer. This meeting is open to the 

public in accordance with the Federal 

Advisory Committee Act (5 U.S.C. App. 

2, section 10(a)). 

DATES: Meeting date: The public 

meeting will be held on Wednesday, 

April 21, 2010 from 7:30 a.m. until 4:30 

p.m., eastern daylight time (e.d.t.). 

Deadline for Submission of Written 

Comments: Written comments must be 

received at the address specified in the 

ADDRESSES section of this notice by 5 

p.m., e.d.t. on March 22, 2010. Once 

submitted all comments are final. 

Deadlines for Speaker Registration 

and Presentation Materials: The 

deadline to register to be a speaker and 

to submit Powerpoint presentation 

materials and writings that will be used 

in support of an oral presentation, is 5 

p.m., e.d.t. on Monday, March 22, 2010. 

Speakers may register by phone or via 

e-mail by contacting the person listed in 

the FOR FURTHER INFORMATION CONTACT

section of this notice. Presentation 

materials must be received at the 

address specified in the ADDRESSES

section of this notice. 

Deadline for All Other Attendees 

Registration: Individuals may register 

via e-mail at 

MEDCAC_Registration@cms.hhs.gov or 

by phone by contacting the person listed 

in the FOR FURTHER INFORMATION

CONTACT section of this notice by 5 p.m., 

e.d.t. on Wednesday, April 14, 2010. 

Deadline for Submitting a Request for 

Special Accommodations: Persons 

attending the meeting who are hearing 

or visually impaired, or have a 

condition that requires special 

assistance or accommodations, are 

asked to contact the Executive Secretary 

for MEDCAC as specified in the FOR

FURTHER INFORMATION CONTACT section of 

this notice no later than 5 p.m., e.d.t. 

Friday, April 2, 2010. 

ADDRESSES: Meeting Location: The 

meeting will be held in the main 

auditorium of the Centers for Medicare 

& Medicaid Services, 7500 Security 

Boulevard, Baltimore, MD 21244. 

Submission of Presentations and 

Comments: Presentation materials and 

written comments that will be presented 

at the meeting must be submitted via email to 

MedCACpresentations@cms.hhs.gov or 

by regular mail to the contact listed in 

the FOR FURTHER INFORMATION CONTACT

section of this notice by the date 

specified in the DATES section of this 

notice. 

FOR FURTHER INFORMATION CONTACT: 

Maria Ellis, Executive Secretary for 

MEDCAC, Centers for Medicare & 

Medicaid Services, Office of Clinical 

Standards and Quality, Coverage and 

Analysis Group, C1–09–06, 7500 

Security Boulevard, Baltimore, MD 

21244 or contact Ms. Ellis by phone 

(410–786–0309) or via e-mail at 

Maria.Ellis@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

MEDCAC, formerly known as the 

Medicare Coverage Advisory Committee 

(MCAC), provides advice and 

recommendations to CMS regarding 

clinical issues. (For more information 

on MCAC, see the December 14, 1998 

Federal Register (63 FR 68780).) This 

notice announces the April 21, 2010, 

public meeting of the Committee. 

During this meeting, the Committee will 

discuss the currently available evidence 

regarding the risks, benefits and 

outcomes of radiation therapy, inclusive 

of EBRT and brachytherapy, for the 

treatment of localized prostate cancer. 

Background information about this 

topic, including panel materials, is 

available at http://www.cms.hhs.gov/ 

coverage. We encourage the 

participation of appropriate 

organizations with expertise in radiation 

therapy for the treatment of localized 

prostate cancer. 


sroberts on DSKD5P82C1PROD with NOTICES
Federal Register / Vol. 75, No. 38 / Friday, February 26, 2010 / Notices 8981 

II. Meeting Format 

This meeting is open to the public. 

The Committee will hear oral 

presentations from the public for 

approximately 45 minutes. The 

Committee may limit the number and 

duration of oral presentations to the 

time available. Your comments should 

focus on issues specific to the list of 

topics that we have proposed to the 

Committee. The list of research topics to 

be discussed at the meeting will be 

available on the following Web site 

prior to the meeting: http:// 

www.cms.hhs.gov/mcd/ 

index_list.asp?list_type=mcac. We 

require that you declare at the meeting 

whether you have any financial 

involvement with manufacturers (or 

their competitors) of any items or 

services being discussed. 

The Committee will deliberate openly 

on the topics under consideration. 

Interested persons may observe the 

deliberations, but the Committee will 

not hear further comments during this 

time except at the request of the 

chairperson. The Committee will also 

allow a 15-minute unscheduled open 

public session for any attendee to 

address issues specific to the topics 

under consideration. At the conclusion 

of the day, the members will vote and 

the Committee will make its 

recommendation(s) to CMS. 

III. Registration Instructions 

CMS’s Coverage and Analysis Group 

is coordinating meeting registration. 

While there is no registration fee, 

individuals must register to attend. You 

may register by contacting the person 

listed in the FOR FURTHER INFORMATION

CONTACT section of this notice by the 

deadline listed in the DATES section of 

this notice. Please provide your full 

name (as it appears on your state-issued 

driver’s license), address, organization, 

telephone, fax number(s), and e-mail 

address. You will receive a registration 

confirmation with instructions for your 

arrival at the CMS complex or you will 

be notified the seating capacity has been 

reached. 

IV. Security, Building, and Parking 

Guidelines 

This meeting will be held in a Federal 

government building; therefore, Federal 

security measures are applicable. We 

recommend that confirmed registrants 

arrive reasonably early, but no earlier 

than 45 minutes prior to the start of the 

meeting, to allow additional time to 

clear security. Security measures 

include the following: 

• Presentation of government-issued 

photographic identification to the 

Federal Protective Service or Guard 

Service personnel. 

• Inspection of vehicle’s interior and 

exterior (this includes engine and trunk 

inspection) at the entrance to the 

grounds. Parking permits and 

instructions will be issued after the 

vehicle inspection. 

• Inspection, via metal detector or 

other applicable means of all persons 

entering the building. We note that all 

items brought into CMS, whether 

personal or for the purpose of 

presentation or to support a 

presentation, are subject to inspection. 

We cannot assume responsibility for 

coordinating the receipt, transfer, 

transport, storage, set-up, safety, or 

timely arrival of any personal 

belongings or items used for 

presentation or to support a 

presentation. 

Note: Individuals who are not registered in 

advance will not be permitted to enter the 

building and will be unable to attend the 

meeting. The public may not enter the 

building earlier than 45 minutes prior to the 

convening of the meeting. All visitors must 

be escorted in areas other than the lower and 

first floor levels in the Central Building. 

Authority: 5 U.S.C. App. 2, section 10(a). 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program) 

Dated: February 4, 2010. 

Barry M. Straube, 

Chief Medical Officer and Director, Office 

of Clinical Standards and Quality, Centers 

for Medicare & Medicaid Services. 

[FR Doc. 2010–3724 Filed 2–25–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Treatment of Glaucoma by 

Administration of Adenosine A3 

Antagonists 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Provisional Patent 

Application 60/010,737, entitled 

‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed January 29, 

1996 [HHS Ref. No. E–225–1995/0–US– 

1], U.S. Provisional Patent Application 

60/021,191, entitled ‘‘Dihydropyridine, 

pyridine-, benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed July 3, 1996 

[HHS Ref. No. E–225–1995/1–US–1], 

PCT Application PCT/US97/01252, 

entitled ‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ filed January 29, 

1997 [HHS Ref. No. E–225–1995/2– 

PCT–1], U.S. Patent 6,066,642, entitled 

‘‘Dihydropyridine, pyridine-, 

benzopyran one-, and 

triazoloquinazoline derivatives, their 

preparation and use as adenosine 

receptor antagonists,’’ issued May 23, 

2000 [HHS Ref. No. E–225–1995/2–US– 

08], Australian Patent 709190, issued 

December 9, 1999 [HHS Ref. No. E–225– 

1995/2–AU–04], European Patent 

Application No. 97905627.2, filed 

January 29, 1997 [HHS Ref. No. E–225– 

1995/2–EP–05], Hong Kong Application 

No. 99102653.6, filed January 29, 1997 

[HHS Ref. No. E–225–1995/2–HK–06], 

Japanese Patent Application No. 

527065/1997, filed January 29, 1997 

[HHS Ref. No. E–225–1995/2–JP–07], 

Australian Patent 755525, issued March 

27, 2003 [HHS Ref. No. E–225–1995/2– 

AU–02], and Canadian Patent 2244774, 

issued October 17, 2006 [HHS Ref. No. 

E–225–1995/2–CA–03], U.S. Provisional 

Patent Application 60/092,292, entitled 

‘‘A3 Adenosine Receptor Antagonists,’’ 

filed July 10, 1998 [HHS Ref. No. E– 

096–1998/0–US–1], PCT Application 

PCT/US99/15562, entitled’’A3 

Adenosine Receptor Antagonists,’’ filed 

July 2, 1999 [HHS Ref. No. E–096–1998/ 

0–PCT–2], U.S. Patent 6,376,521, 

entitled ‘‘A3 Adenosine Receptor 

Antagonists,’’ issued April 23, 2003, 

[HHS Ref. No. E–096–1998/0–US–04], 

and Canadian Patent Application No. 

2336967, filed July 2, 1999 [HHS Ref. 

No. E–096–1998/0–CA–03], U.S. 

Provisional Patent Application 61/ 

085,588, entitled ‘‘Truncated 

Methanacarba Adenosine Derivatives as 

A3 Antagonists,’’ filed August 1, 2008 

[HHS Ref. No. E–285–2008/0–US–1], 

PCT Application PCT/US2009/52439, 

entitled ‘‘Truncated Methanacarba 

Adenosine Derivatives as A3 

Antagonists,’’ filed July 31, 2009 [HHS 

Ref. No. E–285–2008/0–PCT–2], and 

Korean International Application No. 

PCT/KR2007/001131, entitled 


sroberts on DSKD5P82C1PROD with NOTICES